Dupixent® (dupilumab) Late-Breaking Data from NOTUS
NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function,...
Source: globenewswire.com
Page 24 - Forward Looking Statements News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Forward Looking Statements. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Forward Looking Statements Today - Breaking & Trending Today
Sanofi: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly
Source: finanznachrichten.de
Northwest Natural : May 2024 - MarketScreener
Investor Presentation May 2024 Investor Information ...
Source: marketscreener.com
OptiNose, Inc. (NASDAQ:OPTN) Q1 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the OptiNose's Q1 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Source: insidermonkey.com
Chesapeake Utilities : 2024 AGA Financial Forum Presentation
AGA Financial Forum MAY 19 - 21, 2024 Safe Harbor for Forward-Looking Statements ...
Source: marketscreener.com